LINC00309 is associated with short disease-free survival in breast cancer

Long non-coding RNAs play an important role in breast cancer. Even with adjuvant hormone therapy, patients with estrogen receptor positive breast cancer can present with recurrences and distant metastases. We investigated whether the expression of a novel long non-coding RNA LINC00309 can predict th...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell international 2019-08, Vol.19 (1), p.210-210, Article 210
Main Authors: Huang, Sheng, Chi, Yayun, Chi, Weiru, Guo, Rong, Su, Yonghui, Xue, Jingyan, Zhou, Shaoqiang, Wang, Jiankui, Yang, Zhuangqing, Nie, Jianyun, Shao, Zhimin, Chen, Dedian, Wu, Jiong
Format: Article
Language:English
Subjects:
Breast cancer
Endocrine therapy resistance
LINC00309
Long non-coding RNA
Primary Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Long non-coding RNAs play an important role in breast cancer. Even with adjuvant hormone therapy, patients with estrogen receptor positive breast cancer can present with recurrences and distant metastases. We investigated whether the expression of a novel long non-coding RNA LINC00309 can predict the outcome of breast cancer, especially for hormone-receptor positive patients. This retrospective study collected 290 breast cancer patients including 161 patients with hormone-positive. qPCR was performed to detect the expression of LINC00309. Kaplan-Meier and Cox risk proportion model were applied to disclose the function of LINC00309 for breast cancer prognosis. LINC00309 high expression was an independent predictor for worse disease-free survival (  = 2.127; 95% CI 1.074-4.212;  = 0.030) and associated with a shorter disease-free survival (  = 0.027), especially in hormone-positive breast cancer patients ( = 0.001). Also LINC00309 high expression was associated with a shorter disease-free survival both in selective estrogen receptor modulator related hormone therapy ( = 0.025) and aromatase inhibitors related hormone therapy ( = 0.048). Moreover, LINC00309 was an independent predictor of worse disease-free survival in hormone-receptor positive breast cancer patients on univariate (  = 4.505; 95% CI 1.722-11.785;  = 0.002) and multivariate (  = 4.159; 95% CI 1.537-11.251;  = 0.005) analyses. In breast cancer, Linc00309 is significantly associated with poor prognosis and may represent a new marker of prognosis.
ISSN:1475-2867
1475-2867
DOI:10.1186/s12935-019-0887-x